Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lynx Therapeutics Inc.

Latest From Lynx Therapeutics Inc.

Gene Logic appoints Norrie Russell as president

Gene Logic, part of the Indian genomics services company, Ocimum Biosolutions, has appointed Dr Norrie Russell as president. Dr Russell, who comes with more than 30 years of experience in drug discovery, has previously held leadership positions with NovaRx, Invitrogen, Aviva Biosciences and Lynx Therapeutics. He has also worked for AstraZeneca, where he was global head, biological science and technology.

Dr Norrie Russell joins NovaRx

The US biopharmaceutical company NovaRx has named Dr Norrie Russell president and chief operating officer. He has more than 25 years' experience in drug discovery, having previously served as president and CEO of the biotech company Kalos Therapeutics. Dr Russell has also worked at AstraZeneca, Invitrogen, Aviva Biosciences and Lynx Therapeutics.


The A-List: 2004's Trend-Shaping Series A Financings

Analyzing the venture financings closed by 2004's new crop of biotech, diagnostics, and medical device start-ups reveals today's trends that may shape tomorrow's health care industry. Here we point out eleven 2004 Series A financings that identify and illustrate what's hot.

BioPharmaceutical Medical Device

Instrumental Improvement: Solexa Merges With Lynx

Reverse merging into Lynx gives high-throughput sequencing play Solexa the instrument development capabilities, Nasdaq listing and US presence it lacked. What's more, combining Solexa's sequencing technology with the commercial infrastructure at Lynx was enough to secure top-notch management and cash to see the company through to its first product offering, expected as early as late 2005.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics